We examined the prevalence of use and cost impact of DPP-4 inhibitors and GLP-1 receptor agonists in people with diabetes.
Brandeis Seymore, RPh
Advertisement
Articles by Brandeis Seymore, RPh
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
2
GLP-1s and Oncology: The Drug Interaction Clinicians Aren't Talking About
3
The Weekly Dose: Cyclosporiasis Outbreak Grows, AI-Powered Refills Pilot, and New FDA Approvals in Alzheimer Disease, Oncology
4
Improving Detection and Management of ATTR-CM Through Pharmacy Care
5